Exagen Inc

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exagen Inc reports robust Q1 revenue growth and strategic expansion

Exagen Inc's Q1 performance reflects strong revenue growth and improved financial outlook, driven by enhanced ASP and strategic initiatives.
Despite challenges in initial demand impact and regulatory monitoring, the company remains optimistic about future growth prospects and market positioning.
With a focus on innovation, market expansion, and operational efficiency, Exagen Inc aims to capitalize on opportunities for sustained growth and competitive advantage.

Exagen Inc reports strong Q2 performance, eyes growth through innovation

Exagen Inc's Q2 performance reflects significant improvement in financial metrics, revenue growth, and progress towards profitability, driven by increased clinical adoption and strategic initiatives.
The company's focus on innovation, market expansion, and customer engagement through new markers, biopharma contracts, and educational campaigns positions them for sustained growth and competitive advantage.
While challenges persist in achieving profitability and market acceptance, Exagen's proactive approach to addressing these hurdles and leveraging opportunities bodes well for their future success and market leadership.

Exagen Inc reports progress in revenue growth and innovation initiatives

Exagen Inc's Q3 2024 earnings call highlighted both achievements and challenges, with a focus on revenue growth, innovation, and operational improvements. The company is poised for growth with upcoming product launches and a strategic approach to enhancing the clinician experience. Challenges remain in achieving profitability and managing capacity expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript

Shares of Exagen (NASDAQ:XGN) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 83.65% year over year to ($0.34), which beat the estimate of ($0.48).

Recap: Exagen Q3 Earnings

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing

Exagen Inc. Reports Third Quarter 2020 Results

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following November investor conferences.

Exagen Inc. To Participate in November Investor Conferences

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a new study in collaboration with Brigham and Women's Hospital in Boston, MA. The Brigham is acknowledged internationally for its expertise and innovation in patient care, biomedical research, and educational training programs for physicians, scientists, and health care professionals.

Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 after the market close on Tuesday, November 10, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen to Announce Third Quarter Financial Results on November 10, 2020

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology's (ACR) first virtual annual meeting, ACR Convergence 2020. The event is being held online from November 5-9, 2020.

Exagen Showcases Six Scientific Presentations at ACR's First Virtual Annual Meeting in November 2020

SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the publication of a study evaluating the economic benefits AVISE® Lupus testing, titled “Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis using a Multivariate Assay Panel (MAP)” in ACR Open Rheumatology.

New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors

SAN DIEGO, Sept.  29, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases, today announced that it has entered into a preferred provider network agreement with Provider Network of America (PNOA). Under the terms of the agreement, over 8 million PNOA members in the U.S. will have in-network access to Exagen’s unique suite of AVISE® tests for autoimmune disorders, including rheumatoid arthritis and lupus.

Exagen Inc. Announces Agreement with Provider Network of America Expanding Access for AVISE® Tests to 8 Million Members

SAN DIEGO, Sept.  23, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is proud to announce the addition of Ms. Wendy S. Johnson as an additional independent member to its Board of Directors, effective October 1, 2020. Ms. Johnson will also serve on the Audit Committee.

Exagen Appoints Wendy Johnson to Board of Directors

SAN DIEGO, Sept.  21, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the launch of AVISE® Vasculitis AAV, a new testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of ANCA-associated vasculitis (AAV).

Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)

SAN DIEGO, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that its management team will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 15-17, 2020.  Ron Rocca, President and CEO of Exagen, will engage in a fireside chat on September 15 at 2:40 pm EDT.

Exagen to Participate in 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

SAN DIEGO, Aug.  03, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a collaboration with Hospital for Special Surgery (HSS) in New York City. This well-respected institution is the world’s leading academic medical center for autoimmune diseases and musculoskeletal health; for 28 consecutive years it has been among the top-ranked hospitals in the nation for rheumatology and orthopedics.

Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome

SAN DIEGO, July  30, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that Ron Rocca, President and Chief Executive Officer of Exagen, will present at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020, at 2:00 pm EDT. The conference will be a virtual event this year. 

Exagen to Present at the Canaccord Genuity 40th Annual Growth Conference

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2020 Results - Earnings Call Transcript

Testing Experiencing Monthly Sequential Improvement    Record Gross Margins of 63%

Exagen Inc. Reports Second Quarter 2020 Results

AVISE Tests Now Available to 6 Million Humana Military Beneficiaries AVISE Tests Now Available to 6 Million Humana Military Beneficiaries

Exagen Inc. AVISE Testing Now Covered and In-Network with TRICARE East

SAN DIEGO, July  16, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended June 30, 2020 before the market opens on Tuesday, July 28, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:00 AM Eastern Time (5:00 AM Pacific Time).

Exagen to Announce Second Quarter Financial Results on July 28, 2020

Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Exagen (XGN) in Focus: Stock Moves 7.9% Higher

SAN DIEGO, June  17, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it has entered into an exclusive worldwide license agreement with the Ohio State Innovation Foundation for the commercial diagnostic development and marketing rights for a novel blood test using vibrational spectroscopy and metabolomic analysis to differentiate patients with fibromyalgia from rheumatoid arthritis, osteo arthritis, chronic lower back pain and systemic lupus erythematosus.

Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration for a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia

SAN DIEGO, June  03, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a clinical trial in collaboration with Duke University in Durham, NC. The Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living with lupus.

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2020 Results - Earnings Call Transcript

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2019 Results - Earnings Call Transcript

SAN DIEGO, March  24, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja Kammesheidt, Ph.D., as Chief Scientific Officer (CSO).  The addition of Drs. Zack and Kammesheidt to the Exagen team will strengthen the company as it continues to focus on clinical research and development initiatives to serve the needs of healthcare providers and their patients.

Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D.

SAN DIEGO, CA, March  16, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation’s largest integrated laboratory system. The agreement provides preferred access through Sonora Quest in Arizona to Exagen’s AVISE testing. The testing can facilitate improved care through the differential diagnosis, prognosis, monitoring and therapeutic optimization of complex and incurable autoimmune rheumatic diseases. The details of the agreement are confidential.

News for Exagen Inc Stock (XGN)